Lasa Supergenerics
Healthcare
LASA NSE
₹4.44
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Close 2 Nov 2026 ₹4.44 −7.07 −61.4% 1Y
Start ₹11.51
Key Fundamentals
Price-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- −18.20%
- Debt to Equity
- 0.20
- EPS (TTM)
- −₹3.30
- Book Value
- —
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- —
- ROE
- −19.70%
- Dividend Yield
- 3.83%
- EBITDA
- −₹7.20 Cr
- 52W High
- ₹12.48
- 52W Low
- ₹4.44
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Lasa Supergenerics (this company) | ₹4.44 | — | ₹22 Cr | — | 3.83% | −19.70% | −18.20% | ₹6 Cr | −₹17 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.77 | 0.70% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
33 Poor
Data confidence 86/100
Category scores
- Quality
- 23
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 50
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 1
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 28
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 5
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.52 times its book value
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.0% over past five years.
- Company has a low return on equity of -9.95% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 1 | 6 |
| Oscillators | Strong Bullish | 2 | 1 | 6 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Strong Bullish
Bearish
2
Neutral
1
Bullish
6
Overall
Strong Bearish
Bearish
12
Neutral
1
Bullish
6
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 10.56
- Bullish
- MACD (12,26,9)
- −0.63
- Bearish
- SMA (50)
- 6.83
- Bearish
- SMA (200)
- 7.95
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Irregular period |
|---|---|
| 5Y | −34.09% |
| 3Y | −42.28% |
| 1Y | −82.39% |
| TTM | −95.17% |
Net profit
| 10Y | Irregular period |
|---|---|
| 5Y | Turned to loss |
| 3Y | Loss narrowed by ₹5 Cr |
| 1Y | Loss widened by ₹19 Cr |
| TTM | Loss narrowed by ₹16.61 Cr |
Operating cash flow
| 10Y | Irregular period |
|---|---|
| 5Y | Turned negative |
| 3Y | Outflow narrowed by ₹9 Cr |
| 1Y | Outflow widened by ₹5 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Irregular period |
|---|---|
| 5Y | −51.38 pp |
| 3Y | −23.38 pp |
| 1Y | −32.23 pp |
| TTM | −132.89 pp |
Revenue by year
| Mar 2017 | ₹199 Cr |
|---|---|
| Mar 2018 | ₹244 Cr |
| Mar 2019 | ₹170 Cr |
| Mar 2020 | ₹167 Cr |
| Mar 2021 | ₹201 Cr |
| Mar 2022 | ₹137 Cr |
| Mar 2023 | ₹130 Cr |
| Mar 2024 | ₹104 Cr |
| Mar 2025 | ₹142 Cr |
| Mar 2026 | ₹25.00 Cr |
Net profit by year
| Mar 2017 | ₹2.00 Cr |
|---|---|
| Mar 2018 | ₹12.00 Cr |
| Mar 2019 | −₹12.00 Cr |
| Mar 2020 | ₹4.00 Cr |
| Mar 2021 | ₹23.00 Cr |
| Mar 2022 | −₹5.00 Cr |
| Mar 2023 | −₹39.00 Cr |
| Mar 2024 | −₹22.00 Cr |
| Mar 2025 | −₹15.00 Cr |
| Mar 2026 | −₹34.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.56 | 24.3 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.2 | −0.13 | 1.23 |
| Expenses | 26.51 | 23.25 | 25.6 | 26.81 | 29.04 | 38.6 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 | 1.99 | 2.62 |
| Operating Profit | 4.05 | 1.05 | 1.06 | −3.99 | 1.8 | 0.79 | 0.27 | 3.41 | −0.5 | −4 | −0.75 | −2.12 | −1.39 |
| OPM % | 13.25% | 4.32% | 3.98% | −17.48% | 5.84% | 2.01% | 0.82% | 8.71% | −2.5% | −130.72% | −34.09% | — | −113.01% |
| Other Income | 0 | 0.08 | 0 | −8.76 | 0 | 1.95 | 8.91 | −21.52 | −20.44 | 0.01 | 0.02 | −0.42 | −0.38 |
| Interest | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 | 0.13 | 0.14 |
| Depreciation | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.8 | 3.9 | 1.57 | 1.57 | 1.57 | 1.31 | 1.57 |
| PBT | 1.03 | −2.11 | −2.06 | −15.97 | −1.86 | −1.31 | 5.91 | −22.12 | −22.54 | −5.68 | −2.41 | −3.98 | −3.47 |
| Tax % | 580.58% | −99.05% | −29.61% | −4.2% | 46.77% | 146.56% | 7.11% | −35.4% | −6.3% | 10.04% | 5.81% | 4.77% | 3.16% |
| Net Profit | −4.95 | −0.02 | −1.46 | −15.3 | −2.73 | −3.23 | 5.49 | −14.29 | −21.12 | −6.25 | −2.55 | −4.16 | −3.58 |
| EPS (₹) | −0.99 | 0 | −0.29 | −3.05 | −0.54 | −0.64 | 1.1 | −2.85 | −4.22 | −1.25 | −0.51 | −0.83 | −0.71 |
Profit & Loss
₹ Cr| Particulars | Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 25 | 6 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 32 | 15 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | −6 | 2 | 6 | −7 | −8 |
| OPM % | — | 23% | 17% | 7% | 18% | 24% | 12% | −4.9% | 2.1% | 4.5% | −29% | −130% |
| Other Income | 0 | −24 | 3 | 0 | 0 | 0 | −8 | −18 | −9 | −11 | −21 | −1 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 0 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 6 | 6 |
| PBT | 0 | 2 | 15 | −16 | 5 | 30 | −6 | −42 | −19 | −19 | −35 | −16 |
| Tax % | — | −10% | 19% | −25% | 23% | 23% | −13% | −9% | 14% | −24% | −2% | — |
| Net Profit | 0 | 2 | 12 | −12 | 4 | 23 | −5 | −39 | −22 | −15 | −34 | −17 |
| EPS (₹) | — | — | 5.4 | −5.26 | 0.89 | 5.6 | −1.31 | −7.71 | −4.34 | −2.95 | −6.8 | −3.3 |
| Div. Payout % | — | 0% | 0% | 0% | 0% | 4% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 0 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 10 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 7 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 55 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 12 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
Cash Flow
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | −3 | 40 | 41 | 14 | 41 | 9 | −17 | 2 | −3 | −8 |
| Investing | 0 | 0 | −44 | −7 | −2 | −4 | −3 | 11 | 0 | 8 | 0 |
| Financing | 0 | 0 | 4 | −33 | −10 | −36 | 0 | −4 | −2 | −6 | 7 |
| Net Cash Flow | 0 | −3 | 0 | 0 | 2 | 1 | 6 | −10 | 0 | 0 | 0 |
| Free Cash Flow | 0 | −5 | −6 | 29 | 13 | 35 | 12 | −12 | 0 | 5 | −7 |
| CFO/OP | — | −6 | 103 | 397 | 46 | 87 | 73 | 273 | 96 | −45 | 105 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | 1 |
| Inventory Days | — | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | 28 |
| Days Payable | — | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | 33 |
| Cash Conversion Cycle | — | 87 | 51 | −18 | 16 | 42 | 28 | 22 | 37 | 53 | −4 |
| Working Capital Days | — | 15 | −1 | −52 | −13 | 35 | 12 | −17 | −44 | 37 | −102 |
| ROCE % | — | 42% | 13% | −4% | 7% | 17% | 1% | −12% | −6% | −1% | −18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lasa Supergenerics insights
65 extracted metrics across FY16–FY27.
Documents
- Concall · Aug 2021Transcript
- Q3 FY21 concall · Feb 2021Transcript
- Concall · Oct 2020PPT
- Q4 FY20 concall · Jun 2020Transcript PPT
- Q4 FY18 concall · Jun 2018Transcript PPT
- 13 Feb 2026
- 14 Nov 2025
- 13 Aug 2025
- General announcements 19 Oct 2026
Frequently Asked Questions about Lasa Supergenerics
What does Lasa Supergenerics Ltd do?
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
Where is Lasa Supergenerics Ltd (LASA) listed?
Lasa Supergenerics Ltd trades as LASA on the NSE and under code 540702 on the BSE.
Which sector does Lasa Supergenerics Ltd belong to?
Lasa Supergenerics Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Lasa Supergenerics Ltd?
Over the last 52 weeks Lasa Supergenerics Ltd has traded between ₹4.44 and ₹12.48 as of 2 Nov 2026.
Does Lasa Supergenerics Ltd pay dividends?
Lasa Supergenerics Ltd has a dividend yield of 3.83%.
What is the Return on Equity (ROE) of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd reported a return on equity of -19.70%. Its debt-to-equity ratio is 0.20.
Company Information
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LASA.md for Lasa Supergenerics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.